It has now been just over a year since I took over editorship of Prostate Cancer and Prostate Diseases from my dear friends, Roger Kirby and Judd Moul. I wanted to provide an update on the initiatives we undertook in the past year, provide some updated metrics and outline our strategy for moving forward.
In my first editorial, I outlined five areas in which we sought to make important changes. Another area we have made major changes is our editorial board. I sought out the brightest up-and-comers from across the globe and across specialties to join me on this adventure. In the past year, we added 14 new editorial board members from six different countries (USA, UK, Italy, Israel, Australia and Canada) and 4 specialties (urology, medical oncology, radiation oncology and epidemiology). I look to this wave of new members as ambassadors of the journal for both recruiting the best papers, but also as key reviewers, and advisors. I look forward to working with each of them over the coming years. Moving forward, we will continue to solicit the best possible papers. We will continue to strive to return reviews within 30 days. We will continue to publish high-quality primary research and review articles. We will continue our policy of open communication between authors and the editors. This hands-on approach has already seen submissions up 35% this year alone. I fully anticipate that with our turn-around time and visibility being on par or ahead of many other journals that submissions and, especially, high-quality submissions will only increase in the future.
In closing, I am proud of what we have been able to accomplish in just 1 year. Although much work lies ahead, I am pleased with our progress to date and appreciate the support of all the readers, authors, reviewers, editors and publishers. I truly believe the brightest days for Prostate Cancer and Prostate Diseases lie ahead and I am excited to continue leading the ship for another great year to come.
SJ Freedland
Editor
